Skip to main navigation Skip to search Skip to main content

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

Roberta P.A. Manzano, Gholam A. Peyman, Palwasha Khan, Petros E. Carvounis, Muhamet Kivilcim, Min Ren, Jonathan C. Lake, Patricia Chévez-Barrios

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats. Methods: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area. Results: In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann-Whitney U test). Conclusion: Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.

Original languageEnglish (US)
Pages (from-to)804-807
Number of pages4
JournalBritish Journal of Ophthalmology
Volume91
Issue number6
DOIs
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)'. Together they form a unique fingerprint.

Cite this